Methods and kits for treating cluster headache disorders

Abstract

The invention features methods and kits employing bromolysergide in therapies for the treatment of cluster headache disorders.

What is claimed is: 
     
         1 . A method of treating a recurrent cluster headache disorder in a subject in need thereof, said method comprising administering 2-bromolysergic acid diethylamide, or a pharmaceutically acceptable salt thereof, to said subject in an amount sufficient to treat said recurrent cluster headache disorder. 
     
     
         2 . A method of treating a chronic cluster headache disorder in a subject in need thereof, said method comprising administering 2-bromolysergic acid diethylamide, or a pharmaceutically acceptable salt thereof, to said subject in an amount sufficient to treat said chronic cluster headache disorder. 
     
     
         3 . A method of treating an episodic cluster headache disorder in a subject in need thereof, said method comprising administering 2-bromolysergic acid diethylamide, or a pharmaceutically acceptable salt thereof, to said subject in an amount sufficient to treat said episodic cluster headache disorder. 
     
     
         4 . A method of extending the remission period of a subject with a cluster headache disorder, said method comprising administering 2-bromolysergic acid diethylamide, or a pharmaceutically acceptable salt thereof, to said subject while said subject is in remission in an amount sufficient to extend said remission period. 
     
     
         5 . The method of  claim 4 , wherein said cluster headache disorder is episodic cluster headache disorder. 
     
     
         6 . The method of  claim 4 , wherein said cluster headache disorder is chronic cluster headache disorder. 
     
     
         7 . The method of  claim 4 , wherein said subject is experiencing autonomic symptoms characteristic of an impending cluster headache attack. 
     
     
         8 . The method of  claim 1 , wherein a dose of from 20 to 50 μg/kg of 2-bromolysergic acid diethylamide, or a pharmaceutically acceptable salt thereof, is administered to said subject. 
     
     
         9 . The method of  claim 8 , wherein two doses of from 20 to 50 μg/kg of 2-bromolysergic acid diethylamide, or a pharmaceutically acceptable salt thereof, are administered to said subject over a period of 2 to 7 days. 
     
     
         10 . The method of  claim 9 , wherein three doses of from 20 to 50 μg/kg of 2-bromolysergic acid diethylamide, or a pharmaceutically acceptable salt thereof, are administered to said subject over a period of 4 to 20 days. 
     
     
         11 . The method of  claim 1 , wherein a unit dosage form comprising from 1.5 to 5 mg of 2-bromolysergic acid diethylamide, or a pharmaceutically acceptable salt thereof, is administered to said subject. 
     
     
         12 . The method of  claim 11 , wherein two doses of a unit dosage form comprising from 1.5 to 5 mg of 2-bromolysergic acid diethylamide, or a pharmaceutically acceptable salt thereof, are administered to said subject over a period of 2 to 7 days. 
     
     
         13 . The method of  claim 12 , wherein three doses of a unit dosage form comprising from 1.5 to 5 mg of 2-bromolysergic acid diethylamide, or a pharmaceutically acceptable salt thereof, are administered to said subject over a period of 4 to 20 days. 
     
     
         14 . The method of  claim 13 , wherein three doses of a unit dosage form comprising from 1.5 to 3 mg of 2-bromolysergic acid diethylamide, or a pharmaceutically acceptable salt thereof, are administered to said subject over a period of 7 to 12 days. 
     
     
         15 . The method of  claim 14 , wherein three doses of a unit dosage form comprising from 1.5 to 3 mg of 2-bromolysergic acid diethylamide, or a pharmaceutically acceptable salt thereof, are administered to said subject once every five days over a period of 11 days. 
     
     
         16 . The method of  claim 1 , wherein said 2-bromolysergic acid diethylamide, or a pharmaceutically acceptable salt thereof, is administered orally, subcutaneously, intravenously, or intramuscularly. 
     
     
         17 . The method of  claim 1 , wherein said subject has a cluster headache disorder that is refractory to one or more prophylactic therapies. 
     
     
         18 . The method of  claim 17 , wherein said cluster headache disorder is refractory to treatment using corticosteroids, tricyclic antidepressants, calcium channel blockers, beta blockers, anticonvulsants, methysergide, or lithium.